New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Carvykti, Janssen’s CAR-T therapy for patients with relapsed and refractory multiple myeloma.
You may also be interested in...
In contrast with the five COVID-19 vaccines that are approved in the EU under conditional marketing authorizations, the European Medicines Agency has recommended that Valneva’s vaccine receive a standard approval.
England Rejects Funding For Kimmtrak, Onureg & Minjuvi But Says Yes To Idefirix, Evrenzo & Verzenios
Immunocore’s advanced uveal melanoma drug, Kimmtrak, and Hansa’s Idefirix for increasing the chances of a successful kidney transplant are among the latest treatments that NICE has appraised regarding their cost-effectiveness.
Adagrasib, Mirati Therapeutics' treatment for patients with non-small cell lung cancer, is among the latest new medicines that have been submitted for review for potential pan-EU approval.